Open access peer-reviewed chapter

Aldosterone/Mineralocorticoid Receptor Downstream Targets as Novel Therapeutic Targets to Prevent Cardiovascular Remodeling

Written By

Jaime Ibarrola, Frederic Jaisser and Natalia López-Andrés

Submitted: May 22nd, 2019 Reviewed: June 4th, 2019 Published: September 25th, 2019

DOI: 10.5772/intechopen.87232

Chapter metrics overview

613 Chapter Downloads

View Full Metrics

Abstract

The incidence of heart failure (HF) is increasing because of aging of the population. Despite optimal therapy, patients with HF experience disease progression associated with high mortality rates. HF is still the first cause of hospital admission in subjects aged >65 years. The obvious solution for HF epidemics is to prevent new-onset HF with therapies directed specifically to mechanistic targets that are involved in the transition to HF. The mineralocorticoid receptor (MR) and its natural ligand, the hormone aldosterone (Aldo), play important roles during cardiac and arterial remodeling, but the underlying effects are still not understood. MR antagonists are highly recommended for treatment of systolic symptomatic HF. However, adverse effects limit their use in clinical practice. Galectin-3 (Gal-3), neutrophil gelatinase-associated lipocalin (NGAL), and cardiotrophin-1 (CT-1) have been identified as highly focused targets controlling downstream key MR-mediated HF mechanisms. Therefore, interfering with mechanistic pathways involved in downstream MR activation may provide therapeutic alternatives to MR antagonists. The aim of this review is to focus on the role of the MR biotargets in cardiovascular remodeling.

Keywords

  • biotarget
  • galectin-3
  • neutrophil gelatinase-associated lipocalin
  • cardiotrophin-1

1. Introduction

Inappropriate mineralocorticoid signaling has been shown to play an important role in the progression of cardiovascular disease. Aldosterone (Aldo) is a main regulator of renal sodium reabsorption with an overall effect on volemia and blood pressure. Aldo binds to the mineralocorticoid receptor (MR), which works as a transcription factor of the nuclear receptor family present in the kidney and also in various other non-epithelial cells including the heart and the vasculature [1]. Indeed, new extrarenal pathophysiological effects of this hormone have been characterized, extending its actions to the cardiovascular system [2]. A growing body of clinical and preclinical evidence suggests that Aldo and MR play an important pathophysiological role in cardiovascular remodeling by promoting changes involving cardiac hypertrophy, fibrosis, arterial stiffness, as well as in inflammation and oxidative stress [3]. In line with these findings, inappropriate MR activation has been shown to promote cardiovascular remodeling in experimental models [4]. The RALES, EPHESUS, and the EMPHASIS-HF clinical trials demonstrated that the addition of MR antagonists (MRAs) to standard care markedly reduced the overall and cardiovascular mortality in patients with systolic heart failure (HF) [5, 6, 7]. The beneficial effects were mainly associated with a reduction of cardiovascular fibrosis, as assessed by circulating biomarkers of cardiovascular extracellular matrix [8]. Moreover, results of the recently completed REMINDER (impact of eplerenone on CV outcomes in patients post myocardial infarction, clinical trial number NCT01176968) trial and TOPCAT (NCT00094302) trial suggest that MR blockade might be clinically beneficial, respectively, for acute myocardial infarction healing and progression of HF with preserved ejection fraction.

The molecular targets involved in the remodeling processes modulated by Aldo/MR activation in the cardiovascular system need to be more precisely analyzed. Inflammatory processes are tightly linked with fibrosis during cardiovascular remodeling. In addition to profibrotic targets, there is evidence that Aldo/MR may trigger inflammatory processes negatively impacting on cardiovascular remodeling processes. Thus, MR activation and inhibition modulate the expression of several pro-inflammatory molecules that may contribute to the pathogenesis of cardiovascular remodeling: Aldo/MR activation increases monocyte chemoattractant protein-1 (CCL-2), transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF), plasminogen activator inhibitor type-1 (PAI-1), as well as collagen and metalloproteases through MR-dependent mechanisms. The identification of the Aldo/MR-modulated targets in cardiovascular remodeling associated with HF development is actually a medical need. Their inhibition could add therapeutic benefits in patients at high risk for the development of HF and cardiovascular remodeling. In the last years, new candidates to be Aldo/MR biotargets emerged in preclinical and clinical studies, such as galectin-3 (Gal-3), neutrophil gelatinase-associated lipocalin (NGAL), and cardiotrophin-1 (CT-1) (Figure 1).

Figure 1.

Aldo/MR biotargets Gal-3, NGAL, and CT-1 contribute to cardiovascular remodeling and dysfunction in various pathological and clinical conditions.

Advertisement

2. Galectin-3

2.1 Galectin-3 induces fibrosis, inflammation, and oxidative stress

Galectin-3 (Gal-3) is a 29–35 kDa protein, member of a β-galactoside-binding lectin family, localized in the nucleus, cytoplasm, cell surface, and extracellular space [9]. It is composed of a highly conserved N-terminal domain and a C-terminal carbohydrate recognition domain, which interacts with glycoproteins [10]. The damaging effects of Gal-3 have been associated with its capacity to bind matrix proteins such as cell surface receptors (integrins), collagen, elastin, or fibronectin [11]. The expression of this lectin has been reported in many tissues, including the heart, vessels, and kidney [12]. Moreover, Gal-3 is expressed in many cell types of the cardiovascular system such as cardiac fibroblasts [13], vascular smooth muscle cells [14], endothelial cells [15], and inflammatory cells [16]. Gal-3 is involved in numerous physiological and pathological processes, some of which, inflammation and fibrosis, are pivotal contributing to pathophysiological mechanisms in the development and progression of HF. Indeed, it has been demonstrated in cell culture that Gal-3 turns quiescent fibroblasts into myofibroblasts that produce and secrete matrix proteins, including collagens [13, 17]. Gal-3 exerts its effects during several other stages of fibrogenesis besides collagen production, such as collagen maturation, externalization, and cross-linking, which underscores the pivotal importance of Gal-3 in cardiovascular fibrosis. Moreover, Gal-3 has emerged as a potential mediator of cardiac damage in different pathological situations through its ability to stimulate key pro-inflammatory molecules [16]. Thus, it has been demonstrated that in human cardiac fibroblasts, Gal-3 enhances the production and the secretion of pro-inflammatory and profibrotic mediators such as interleukin (IL)-1β, IL-6, CCL-2, collagen type I, collagen type III, and fibronectin as well as the activity of MMP-1, MMP-2, and MMP-9 [18]. The in vitro findings have been corroborated by animal studies. Thus, Gal-3 administration induces cardiac fibrosis leading to cardiac dysfunction in rats [13]. Additionally, a new line of evidence points out that Gal-3 is involved in reactive oxygen species (ROS) production, although the mechanisms have not been elucidated. Gal-3 increases the expression of Nox4 in cardiac cells and could regulate Nox4-derived ROS levels during cardiac fibrosis [19]. Moreover, Gal-3 downregulates peroxiredoxin-4 inducing a decrease in total antioxidant capacity and a consequent increase in peroxide production and in oxidative stress markers in cardiac fibroblasts [20]. Additionally, Gal-3 downregulates the protective fumarate hydratase increasing fumarate production in human cardiac fibroblasts, leading to increased ROS levels and increased collagen production [21].

2.2 Galectin-3 as a mediator of Aldo/MR activation

Preclinical studies have demonstrated that Gal-3 is a key mediator of cardiovascular and renal fibrosis and dysfunction in pathological conditions associated with high Aldo levels [14, 18, 22, 23, 24]. In addition, hyperaldosteronism worsens hypertension-induced cardiovascular fibrosis through an increase of Gal-3 [25]. A summary of Gal-3 mediating Aldo/MR effects is shown in Figure 2.

Figure 2.

Gal-3 as a mediator of Aldo/MR effects on fibrosis in several cells and tissues.

2.2.1 Aldosterone/MR regulates galectin-3 expression in vitro

In vitro, in primary cultured vascular smooth muscle cells (VSMCs), Calvier and co-workers described that Aldo increases Gal-3 expression in a dose- and time-dependent manner via its MR [14]. Gal-3, via its lectin activity, is a necessary mediator allowing Aldo-induced collagen type I synthesis, because the blockade of Gal-3 with carbohydrates such as modified citrus pectin (MCP, a complex water-soluble indigestible polysaccharide rich in β-galactose) or N-Acetyl-D-lactosamine abolishes Aldo-induced collagen type I deposition. In confirmation of the pharmacological data, Gal-3-depleted VSMCs are resistant to Aldo profibrotic effects, especially collagen type I deposition [14].

In human cardiac fibroblasts, Aldo also increased Gal-3 expression via its MR, and Gal-3 and Aldo enhance pro-inflammatory and profibrotic markers, as well as metalloproteinase activities, those effects being not observed in Gal-3-silenced cells treated with Aldo [18].

In line with these observations, it has been described that Aldo induces Gal-3 secretion in inflammatory cells (macrophage cell lines THP-1 and RAW 264.7 cells) through MR and via PI3K/Akt and NF-kB transcription signaling pathways [26], amplifying the inflammatory response.

Finally, unpublished data from our group confirmed Gal-3 induction by Aldo via MR in other cell types such and renal cells and 3T3-L1 adipocytes.

2.2.2 Beneficial effects of galectin-3 blockade in experimental models with high aldosterone

In vivo, it has been shown that rats treated with Aldo-salt for 3 weeks present hypertension and display vascular hypertrophy, inflammation, fibrosis, and increased aortic Gal-3 expression. Spironolactone or MCP treatment reverses all the above effects. Interestingly, MCP also blunts Aldo-induced hypertension. In wild-type (WT) and Gal-3 knockout (KO) mice treated with Aldo for 6 hours or 3 weeks—a normotensive model—Aldo increases aortic Gal-3 expression, inflammation, and collagen type I in WT mice at both the short- and the long-term, whereas no changes occur in Gal-3 KO mice. Altogether, these data show that Gal-3 is required for the inflammatory and fibrotic responses to Aldo in VSMCs in vivo, suggesting a key role for Gal-3 in vascular fibrosis [14]. While using the same experimental models, downstream in vitro experiments in human cardiac fibroblasts and the influence of Gal-3 on Aldo-mediated cardiac and renal effects have been also explored. Hypertensive Aldo-salt-treated rats present cardiac and renal hypertrophy (at morphometric, cellular, and molecular levels) and dysfunction. Cardiac and renal expressions of Gal-3 as well as levels of molecular markers attesting fibrosis are also augmented by Aldo-salt treatment. Spironolactone or MCP treatment reverses all of these effects. In WT mice, Aldo does not alter blood pressure levels but increases cardiac and renal Gal-3 expression, fibrosis, and renal epithelial-mesenchymal transition (i.e., renal epithelial cells differentiate onto extracellular matrix secreting and profibrotic myofibroblasts). Gal-3 KO mice are resistant to Aldo-induced deleterious cardiorenal effects [22].

Aldo levels are increased in spontaneously hypertensive rats (SHR) [27], as well as in hypertensive patients [28], being considered as an inducer of hypertensive organ damage [29]. MR activation and high salt intake cause hypertension as well as inflammation, leading to cardiac inflammation and fibrosis [30]. Gal-3 levels, as well as cardiorenal inflammation and fibrosis, are also increased in the myocardium and kidney from SHR as compared to normotensive controls. Gal-3 pharmacological inhibition using MCP exerts beneficial effects, diminishing cardiorenal inflammation and fibrosis in the absence of blood pressure modifications [18, 23, 31].

Obesity is frequently associated with increased Aldo concentrations in humans [32] and is considered as HF stage A [33]. Obesity upregulates Gal-3 production in the cardiovascular and in the renal system in a normotensive animal model of diet-induced obesity by feeding for 6 weeks a high-fat diet, while Gal-3 inhibition with MCP reduces cardiovascular and renal levels of Gal-3, fibrosis, and inflammation in obese animals without changes in body weight or blood pressure [34]. In adipose tissue, obese male Wistar rats fed with a high-fat diet for 6 weeks present an increase in Gal-3 levels that are accompanied by an increase in pericellular collagen. Obese rats exhibit higher adipose tissue inflammation, as well as enhanced differentiation degree of the adipocytes. Treatment with MCP prevents all the above effects [24]. In summary, Gal-3 emerges as a potential therapeutic target in adipose tissue remodeling associated with obesity—a condition associated with hyperaldosteronemia—and could have an important role in the development of metabolic, cardiovascular, and renal alterations associated with obesity.

In theory, MR activation can promote aortic sclerosis and aortic stenosis (AS), due to its effect on inflammation and fibrosis. Once aortic valve disease has been established, the pressure or volume overload may induce left ventricular dysfunction. In a normotensive animal model of pressure overload (AS), cardiac, vascular, and renal Gal-3 is augmented, and its pharmacological inhibition with MCP prevents cardiovascular and renal functional alterations as well as cardiovascular and renal fibrosis and inflammation [21, 34, 35].

The acute administration of MRAs, either before the onset of ischemia or at the moment of reperfusion, profoundly reduces infarct size (reviewed in [36]). In an animal model of ischemia–reperfusion, cardiac Gal-3 is augmented, and its pharmacological inhibition with MCP prevented cardiac functional, histological, and molecular alterations (unpublished data from our group).

2.2.3 Aldosterone-galectin-3 in clinical populations

As mentioned above, Aldo increases Gal-3 expression in the cardiovascular and renal system as well as in adipose tissue in experimental models.

In a cohort of patients with Aldo-producing adenoma, the authors demonstrated that Gal-3 levels are enhanced. Interestingly, 1 year after adrenalectomy, plasma Gal-3 levels decrease, reinforcing the relation of Aldo-Gal-3 and confirming the results obtained using preclinical models [26]. In contrast with these observations, another group recently described that Gal-3 levels are not increased in patients with primary hyperaldosteronism (as compared to hypertensive patients) and levels do not decrease after adrenalectomy [37].

In untreated congestive HF, Aldo plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment [38]. Interestingly, the serum Gal-3 level has been correlated with serum markers of cardiac extracellular matrix turnover in HF patients, and, therefore, Gal-3 emerges as a biomarker associated with HF onset, morbidity, and mortality [39].

In morbidly obese patients presenting high Aldo levels, insulin resistance, and left ventricular hypertrophy, high Gal-3 levels are associated with a worsening of diastolic function [23]. Moreover, in patients with AS, cardiac Gal-3 is increased and associates with markers of myocardial fibrosis and inflammation [35]. Interestingly, both Aldo and Gal-3 are increased in pulmonary arterial hypertension patients. The axis Aldo/Gal-3 is relevant in pulmonary arterial hypertension because plasma levels of both molecules are associated with pulmonary arterial hypertension severity [40]. Furthermore, Gal-3 positively correlated with Nox4 (related to oxidative stress production) in pulmonary arterial hypertension patients [41].

Given the intimate relation between Aldo, Gal-3, and cardiovascular fibrosis, the predictive value of Gal-3 in patients treated with MRAs has been analyzed. In a cohort of HF patients, MRA treatment does not alter the prognostic value of Gal-3 [42]. An analysis examining the interaction between baseline Gal-3 levels and MRA therapy on outcomes shows no difference in patients who were receiving MRA [43]. Moreover, among patients with chronic HF and elevated Gal-3 concentrations, there is no specific benefit from addition or intensification of MRA therapy [44].

Advertisement

3. NGAL

3.1 NGAL induces fibrosis and inflammation

NGAL, also known as lipocalin-2, 24p3, siderocalin, or uterocalin, is a small glycoprotein of 25 kDa member of the lipocalin family. NGAL is expressed by different cell types including renal, endothelial, VSMCs, macrophages, dendritic cells, cardiomyocytes or cardiac fibroblasts (reviewed in [45]).

NGAL is involved in a wide variety of pathological situations as cardiovascular and renal diseases. Indeed, it has been demonstrated in cell culture that NGAL enhances the production and the secretion of pro-inflammatory and profibrotic mediators such as interleukin (IL)-1β, IL-6, CCL-2, osteopontin, collagen type I, and collagen type III in human cardiac fibroblasts [46, 47]. NGAL also increases collagen type I production as well as CT-1 and Gal-3 expression and secretion in VSMCs [48]. In cardiac cells, NGAL can also activate the inflammatory pathway NF-kB [47]. Moreover, NGAL treatment induces migration of neutrophils [49], and NGAL KO mice have been shown to present reduced chemotaxis and adhesion [50]. Moreover, NGAL KO mice subjected to ischemia/reperfusion do not present immune cell recruitment [51].

3.2 NGAL as a mediator of Aldo/MR activation

In vitro, in HL-1 cardiomyocytes, Aldo induces NGAL expression via its MR [52]. These results have been also expanded to other cell types such as cardiac fibroblasts, where Aldo also enhances NGAL expression [47].

Preclinical studies have demonstrated that NGAL is a key mediator of cardiovascular and renal fibrosis, inflammation, and dysfunction in pathological conditions associated with high Aldo levels. Firstly, NGAL has been found to be increased in mice overexpressing MR in cardiomyocytes [52]. Moreover, NGAL KO mice have been found to be resistant to Aldo-salt-induced hypertension and vascular fibrosis [48]. Interestingly, NGAL KO mice subjected to myocardial infarction show lower cardiac fibrosis and inflammation as well as improved cardiac function [47]. Recently it has been described using mice depleted for NGAL in their immune cells by bone marrow transplantation that NGAL from immune cells is mandatory for Aldo-induced cardiac fibrosis and inflammation [53].

In hypertensive patients, NGAL plasma concentrations are elevated and correlate with blood pressure levels [54]. NGAL serum levels are also increased in myocardial infarction patients and in HF patients [55, 56], as well as in obese patients [57]. Importantly, the rise of the complex NGAL/MMP-9 in obese subjects (stage A HF) and its association with plasma Aldo levels suggest that NGAL may serve as a biomarker of MR activation [48].

Advertisement

4. Cardiotrophin-1

4.1 Cardiotrophin-1 induces fibrosis and inflammation

CT-1 is a member of the interleukin-6 superfamily, which is expressed in different tissues including the heart, vessels, skeletal muscle, liver, lung, adipose tissue, and kidney [58, 59]. In the myocardium, CT-1 is produced by both cardiomyocytes and fibroblasts, exerting its action through the glycoprotein 130 (gp130)/leukemia inhibitory factor receptor (LIFR) heterodimer. Whereas CT-1 was initially described as a stress-response factor promoting cardiomyocyte survival [60], chronic exposure to this cytokine induces cardiomyocyte hypertrophy and dysfunction [61, 62]. In addition, experimental in vitro findings in rodent and canine fibroblasts [63, 64, 65, 66] as well as in VSMCs [67] suggest that CT-1 behaves also as a profibrotic factor. In particular, CT-1 induces fibroblast growth and proliferation and collagen production. Moreover, in human cardiac fibroblasts, CT-1 has been shown to stimulate myofibroblast differentiation and collagen type I and III production [68]. Coherently, rats chronically exposed to CT-1 present increased fibrosis in the cardiovascular and in the renal system characterized by increased collagen deposition [62]. Finally, data in chronic HF patients indicate that an association exists between CT-1 and collagen type I and III production in the myocardium [68].

4.2 Cardiotrophin-1 as a mediator of Aldo/MR activation

In vitro, in HL-1 cardiomyocytes, Aldo induces CT-1 in a dose- and time-dependent manner via its MR and through the activation of p38MAPK signaling pathway [69]. Moreover, Aldo also enhances CT-1 expression in VSMCs [67]. Interestingly, CT-1 blockade with specific antibodies avoids Aldo-induced hypertrophy of cardiomyocytes. According to the in vitro data, CT-1-null mice subjected to acute Aldo treatment are resistant to Aldo-induced expression of hypertrophic markers [69]. These results were confirmed in other studies demonstrating that in experimental hyperaldosteronism, the increase of cardiac CT-1 expression is associated with parameters showing left ventricular hypertrophy and fibrosis. Moreover, CT-1-null mice are resistant to Aldo-induced left ventricular hypertrophy and fibrosis [70].

CT-1 expression has been found to be increased in the myocardium of HF patients of different etiologies [68, 71]. Importantly, and according to the results obtained in experimental models, in HF patients high Aldo levels are associated with high CT-1 levels [72].

Advertisement

Acknowledgments

This publication is based upon work from the EU COST Action ADMIRE BM1301 in Aldosterone and Mineralocorticoid Receptor Physiology and Pathophysiology (www.admirecosteu.com).

References

  1. 1. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombès M. The mineralocorticoid receptor: Insights into its molecular and (patho)physiological biology. Nuclear Receptor Signaling. 2007;5:e012. Available from: https://www.nursa.org/NRS/nrs05012.pdf
  2. 2. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Molecular and Cellular Endocrinology. 2012;350(2):266-272. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21784127
  3. 3. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65(2):257-263. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25368026
  4. 4. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz. 2000;25(3):299-306. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10904856
  5. 5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine. 2003;348(14):1309-1321. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa030207
  6. 6. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. The New England Journal of Medicine. 1999;341(10):709-717. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199909023411001
  7. 7. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. The New England Journal of Medicine. 2011;364(1):11-21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21073363
  8. 8. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES) . Rales investigators. Circulation. 2000;102(22):2700-2706. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11094035
  9. 9. Dumic J, Dabelic S, Flögel M. Galectin-3: An open-ended story. Biochimica et Biophysica Acta. 2006;1760(4):616-635. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0304416505004083
  10. 10. Dennis JW, Pawling J, Cheung P, Partridge E, Demetriou M. UDP-N-acetylglucosamine:alpha-6-D-mannoside beta1,6 N-acetylglucosaminyltransferase V (Mgat5) deficient mice. Biochimica et Biophysica Acta. 2002;1573(3):414-422. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12417426
  11. 11. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconjugate Journal. 2002;19(7-9):527-535. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14758076
  12. 12. Kim H, Lee J, Hyun JW, Park JW, Joo H, Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biology International. 2007;31(7):655-662. Available from: http://doi.wiley.com/10.1016/j.cellbi.2006.11.036
  13. 13. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121-3128. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15520318
  14. 14. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33(1):67-75. Available from: http://atvb.ahajournals.org/cgi/doi/10.1161/ATVBAHA.112.300569
  15. 15. Wan SY, Zhang TF, Ding Y. Galectin-3 enhances proliferation and angiogenesis of endothelial cells differentiated from bone marrow mesenchymal stem cells. Transplantation Proceedings. 2011;43(10):3933-3938. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0041134511015272
  16. 16. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(3):433-440. Available from: http://atvb.ahajournals.org/cgi/doi/10.1161/ATVBAHA.107.159160
  17. 17. Yu L, Ruifrok WPT, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circulation. Heart Failure. 2013;6(1):107-117. Available from: http://circheartfailure.ahajournals.org/cgi/doi/10.1161/CIRCHEARTFAILURE.112.971168
  18. 18. Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental Hyperaldosteronism and hypertension novelty and significance. Hypertension. 2015;66(4):767-775. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26238446
  19. 19. He J, Li X, Luo H, Li T, Zhao L, Qi Q , et al. Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4. Journal of the American Society of Hypertension. 2017;11(5):275-289.e2. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1933171117300980
  20. 20. Ibarrola J, Arrieta V, Sádaba R, Martinez-Martinez E, Garcia-Peña A, Alvarez V, et al. Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: A new pathway to induce cardiac damage. Clinical Science (London, England). 2018;132(13):1471-1485. Available from: http://clinsci.org/lookup/doi/10.1042/CS20171389
  21. 21. Ibarrola J, Martínez-Martínez E, Sádaba J, Arrieta V, García-Peña A, Álvarez V, et al. Beneficial effects of Galectin-3 blockade in vascular and aortic valve alterations in an experimental pressure overload model. International Journal of Molecular Sciences. 2017;18(8):1664. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28758988
  22. 22. Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC: Heart Failure. 2015;3(1):59-67. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2213177914003886
  23. 23. Martínez-Martínez E, López-Ándres N, Jurado-López R, Rousseau E, Bartolomé MV, Fernández-Celis A, et al. Galectin-3 participates in cardiovascular Remodeling associated with ObesityNovelty and significance. Hypertension. 2015;66(5):961-969. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26351031
  24. 24. Martínez-Martínez E, Calvier L, Rossignol P, Rousseau E, Fernández-Celis A, Jurado-López R, et al. Galectin-3 inhibition prevents adipose tissue remodelling in obesity. International Journal of Obesity. 2016;40(6):1034-1038. Available from: http://www.nature.com/doifinder/10.1038/ijo.2016.19
  25. 25. Azibani F, Benard L, Schlossarek S, Merval R, Tournoux F, Fazal L, et al. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension (Dallas, Texas 1979). 2012;59(6):1179-1187. Available from: http://hyper.ahajournals.org/cgi/doi/10.1161/HYPERTENSIONAHA.111.190512
  26. 26. Lin Y-H, Chou C-H, Wu X-M, Chang Y-Y, Hung C-S, Chen Y-H, et al. Aldosterone induced galectin-3 secretion in vitro and in vivo: From cells to humans. Syn W-K, editor. PLoS One. 2014;9(9):e95254. Available from: http://dx.plos.org/10.1371/journal.pone.0095254
  27. 27. Sowers J, Tuck M, Asp ND, Sollars E. Plasma aldosterone and corticosterone responses to adrenocorticotropin, angiotensin, potassium, and stress in spontaneously hypertensive rats. Endocrinology. 1981;108(4):1216-1221. Available from: https://academic.oup.com/endo/article-lookup/doi/10.1210/endo-108-4-1216
  28. 28. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109(10):1284-1291. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/01.CIR.0000121426.43044.2B
  29. 29. Zia AA, Kamalov G, Newman KP, McGee JE, Bhattacharya SK, Ahokas RA, et al. From aldosteronism to oxidative stress: The role of excessive intracellular calcium accumulation. Hypertension Research. 2010;33(11):1091-1101. Available from: http://www.nature.com/articles/hr2010159
  30. 30. Amador CA, Barrientos V, Peña J, Herrada AA, González M, Valdés S, et al. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension (Dallas, Texas 1979). 2014;63(4):797-803. Available from: http://hyper.ahajournals.org/lookup/doi/10.1161/HYPERTENSIONAHA.113.02883
  31. 31. Martinez-Martinez E, Jurado-Lopez R, Valero-Munoz M, Bartolome MV, Ballesteros S, Luaces M, et al. Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: Potential role in obesity. Journal of Hypertension. 2014;32(5):1104-1114. discussion 1114
  32. 32. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356-362. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15630041
  33. 33. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and Management of Chronic Heart Failure in the adult: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154-e235. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16160202
  34. 34. Martinez-Martinez E, Ibarrola J, Calvier L, Fernandez-Celis A, Leroy C, Cachofeiro V, et al. Galectin-3 blockade reduces renal fibrosis in two normotensive experimental models of renal damage. Rouet P, editor. PLoS One. 2016;11(11):e0166272. Available from: http://dx.plos.org/10.1371/journal.pone.0166272
  35. 35. Arrieta V, Martinez-Martinez E, Ibarrola J, Alvarez V, Sádaba R, Garcia-Peña A, et al. A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis. Clinical Science (London, England). 2017;131(10):935-949. Available from: http://clinsci.org/lookup/doi/10.1042/CS20170145
  36. 36. van den Berg TNA, Rongen GA, Fröhlich GM, Deinum J, Hausenloy DJ, Riksen NP. The cardioprotective effects of mineralocorticoid receptor antagonists. Pharmacology & Therapeutics. 2014;142(1):72-87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24275323
  37. 37. van den Berg TNAD, Meijers WC, Donders ART, Van Herwaarden AE, Rongen GA, de Boer RA, et al. Plasma galectin-3 concentrations in patients with primary aldosteronism. Journal of Hypertension. 2017;35(9):1849-1856. Available from: http://insights.ovid.com/crossref?an=00004872-201709000-00019
  38. 38. Zannad F. Aldosterone and heart failure. European Heart Journal. 1995;16(Suppl N):98-102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8682070
  39. 39. Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF (cardiac resynchronization in heart failure) trial. European Journal of Heart Failure. 2012;14(1):74-81. Available from: http://doi.wiley.com/10.1093/eurjhf/hfr151
  40. 40. Calvier L, Legchenko E, Grimm L, Sallmon H, Hatch A, Plouffe BD, et al. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart. 2016;102(5):390-396. Available from: http://heart.bmj.com/lookup/doi/10.1136/heartjnl-2015-308365
  41. 41. He J, Li X, Luo H, Li T, Zhao L, Qi Q , et al. Galectin-3 mediates the pulmonary arterial hypertension–induced right ventricular remodeling through interacting with NADPH oxidase 4. Journal of the American Society of Hypertension. 2017;11(5):275-289.e2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28431936
  42. 42. Koukoui F, Desmoulin F, Galinier M, Barutaut M, Caubère C, Evaristi MF, et al. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists. Mischak H, editor. PLoS One. 2015;10(3):e0119160. Available from: http://dx.plos.org/10.1371/journal.pone.0119160
  43. 43. Fiuzat M, Schulte PJ, Felker M, Ahmad T, Neely M, Adams KF, et al. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: Analysis from HF-ACTION. Journal of Cardiac Failure. 2014;20(1):38-44. Available from: http://linkinghub.elsevier.com/retrieve/pii/S107191641301261X
  44. 44. Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, et al. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. American Heart Journal. 2015;169(3):404-411.e3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25728731
  45. 45. Buonafine M, Martinez-Martinez E, Jaisser F. More than a simple biomarker: The role of NGAL in cardiovascular and renal diseases. Clinical Science (London, England). 2018;132(9):909-923. Available from: http://clinsci.org/lookup/doi/10.1042/CS20171592
  46. 46. Buonafine M, Martínez-Martínez E, Amador C, Gravez B, Ibarrola J, Fernández-Celis A, et al. Neutrophil Gelatinase-associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. Journal of Molecular and Cellular Cardiology. 2018;115:32-38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29289651
  47. 47. Martinez-Martinez E, Buonafine M, Boukhalfa I, Ibarrola J, Fernandez-Celis A, Kolkhof P, et al. Aldosterone target NGAL (neutrophil Gelatinase-associated Lipocalin) is involved in cardiac Remodeling after myocardial infarction through NFkappaB pathway. Hypertension (Dallas, Texas 1979). 2017;70(6):1148-1156
  48. 48. Tarjus A, Martínez-Martínez E, Amador C, Latouche C, El Moghrabi S, Berger T, et al. Neutrophil Gelatinase-associated Lipocalin, a novel mineralocorticoid biotarget, mediates vascular Profibrotic effects of mineralocorticoids. Hypertension (Dallas, Texas 1979). 2015;66(1):158-166. Available from: http://hyper.ahajournals.org/lookup/doi/10.1161/HYPERTENSIONAHA.115.05431
  49. 49. Schroll A, Eller K, Feistritzer C, Nairz M, Sonnweber T, Moser PA, et al. Lipocalin-2 ameliorates granulocyte functionality. European Journal of Immunology. 2012;42(12):3346-3357. Available from: http://doi.wiley.com/10.1002/eji.201142351
  50. 50. Shao S, Cao T, Jin L, Li B, Fang H, Zhang J, et al. Increased Lipocalin-2 contributes to the pathogenesis of psoriasis by modulating neutrophil Chemotaxis and cytokine secretion. The Journal of Investigative Dermatology. 2016;136(7):1418-1428. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022202X16308703
  51. 51. Aigner F, Maier HT, Schwelberger HG, Wallnöfer EA, Amberger A, Obrist P, et al. Lipocalin-2 regulates the inflammatory response during ischemia and reperfusion of the transplanted heart. American Journal of Transplantation. 2007;7(4):779-788. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17391123
  52. 52. Latouche C, El Moghrabi S, Messaoudi S, Nguyen Dinh Cat A, Hernandez-Diaz I, Alvarez de la Rosa D, et al. Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension (Dallas, Texas 1979). 2012;59(5):966-972. Available from: http://hyper.ahajournals.org/cgi/doi/10.1161/HYPERTENSIONAHA.111.187872
  53. 53. Buonafine M, Martinez-Martinez E, Amador C, Gravez B, Ibarrola J, Fernandez-Celis A, et al. Neutrophil Gelatinase-associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. Journal of Molecular and Cellular Cardiology. 2017;115:32-38
  54. 54. Ong K-L, Tso AWK, Cherny SS, Sham P-C, Lam T-H, Lam KSL, et al. Role of genetic variants in the gene encoding lipocalin-2 in the development of elevated blood pressure. Clinical and Experimental Hypertension. 2011;33(7):484-491. Available from: http://www.tandfonline.com/doi/full/10.3109/10641963.2010.549276
  55. 55. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. European Journal of Heart Failure. 2008;10(10):997-1000. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18804416
  56. 56. Yndestad A, Landrø L, Ueland T, Dahl CP, Flo TH, Vinge LE, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. European Heart Journal. 2009;30(10):1229-1236. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehp088
  57. 57. Wang Y. Small lipid-binding proteins in regulating endothelial and vascular functions: Focusing on adipocyte fatty acid binding protein and lipocalin-2. British Journal of Pharmacology. 2012;165(3):603-621. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21658023
  58. 58. Escoté X, Gómez-Zorita S, López-Yoldi M, Milton-Laskibar I, Fernández-Quintela A, Martínez JA, et al. Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in obesity and diabetes development. International Journal of Molecular Sciences. 2017;18(8):1770. Available from: http://www.mdpi.com/1422-0067/18/8/1770
  59. 59. López-Andrés N, Calvier L, Labat C, Fay R, Díez J, Benetos A, et al. Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension (Dallas, Texas 1979). 2013;61(1):120-129. Available from: http://hyper.ahajournals.org/cgi/doi/10.1161/HYPERTENSIONAHA.112.201699
  60. 60. López N, Díez J, Fortuño MA. Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine. 2005;30(5):282-292. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15927854
  61. 61. López N, Díez J, Fortuño MA. Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. Journal of Molecular and Cellular Cardiology. 2006;41(5):902-913. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17014864
  62. 62. López-Andrés N, Rousseau A, Akhtar R, Calvier L, Iñigo C, Labat C, et al. Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension (Dallas, Texas 1979). 2012;60(2):563-573. Available from: http://hyper.ahajournals.org/cgi/doi/10.1161/HYPERTENSIONAHA.112.194407
  63. 63. Tsuruda T, Jougasaki M, Boerrigter G, Huntley BK, Chen HH, D’Assoro AB, et al. Cardiotrophin-1 stimulation of cardiac fibroblast growth: Roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type a receptor. Circulation Research. 2002;90(2):128-134. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11834704
  64. 64. Freed DH, Moon MC, Borowiec AM, Jones SC, Zahradka P, IMC D. Cardiotrophin-1: Expression in experimental myocardial infarction and potential role in post-MI wound healing. Molecular and Cellular Biochemistry. 2003;254(1-2):247-256. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14674704
  65. 65. Freed DH, Borowiec AM, Angelovska T, IMC D. Induction of protein synthesis in cardiac fibroblasts by cardiotrophin-1: Integration of multiple signaling pathways. Cardiovascular Research. 2003;60(2):365-375. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14613866
  66. 66. Drobic V, Cunnington RH, Bedosky KM, Raizman JE, Elimban VV, Rattan SG, et al. Differential and combined effects of cardiotrophin-1 and TGF-β 1 on cardiac myofibroblast proliferation and contraction. American Journal of Physiology-Heart and Circulatory Physiology. 2007;293(2):H1053-H1064. Available from: http://www.physiology.org/doi/10.1152/ajpheart.00935.2006
  67. 67. Lopez-Andres N, Fortuno MA, Diez J, Zannad F, Lacolley P, Rossignol P. Vascular effects of cardiotrophin-1: A role in hypertension? Journal of Hypertension. 2010;28(6):1261-1272. Available from http://www.ncbi.nlm.nih.gov/pubmed/20216087
  68. 68. López B, González A, Querejeta R, Larman M, Rábago G, Díez J. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension (Dallas, Texas 1979). 2014;63(3):483-489. Available from: http://hyper.ahajournals.org/cgi/doi/10.1161/HYPERTENSIONAHA.113.02654
  69. 69. López-Andrés N, Iñigo C, Gallego I, Díez J, Fortuño MA. Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. Endocrinology. 2008;149(10):4970-4978. Available from: https://academic.oup.com/endo/article-lookup/doi/10.1210/en.2008-0120
  70. 70. López-Andrés N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA, et al. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. American Journal of Physiology-Heart and Circulatory Physiology. 2011;301(6):H2372-H2382. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21926338
  71. 71. Zolk O, Ng LL, O’Brien RJ, Weyand M, Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation. 2002;106(12):1442-1446. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12234945
  72. 72. López B, González A, Querejeta R, Barba J, Díez J. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: Potential diagnostic implications. Journal of Hypertension. 2009;27(2):418-424. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19155793

Written By

Jaime Ibarrola, Frederic Jaisser and Natalia López-Andrés

Submitted: May 22nd, 2019 Reviewed: June 4th, 2019 Published: September 25th, 2019